Cystatin C: A Strong Marker for Lower Limb Ischemia in Chinese Type 2 Diabetic Patients?

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Liu, Fang ^a   Shen, Jing ^a   Zhao, Jun ^a   Zeng, Hui ^a   Li, Lianxi ^a   Zhao, Jungong ^a   Lu, Fengdi ^a   Bao, Yuqian ^a   Jia, Weiping ^a  

^a SHANGHAI JIAO TONG UNIVERSITY AFFILIATED SIXTH PEOPLE S HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; CREATININE; CYSTATIN C; GAMMA GLUTAMYLTRANSFERASE; GLYCOSYLATED ALBUMIN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; UREA; URIC ACID;

AGE DISTRIBUTION; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BRAIN INFARCTION; CHINESE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CREATININE BLOOD LEVEL; CROSS-SECTIONAL STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DISEASE DURATION; DISEASE MARKER; ENZYME BLOOD LEVEL; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; HYPERTENSION; LEG ISCHEMIA; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; RISK FACTOR; UREA NITROGEN BLOOD LEVEL; URIC ACID BLOOD LEVEL;

AGE FACTORS; AGED; ARTERIES; BIOLOGICAL MARKERS; CROSS-SECTIONAL STUDIES; CYSTATIN C; DIABETES MELLITUS, TYPE 2; DIABETIC FOOT; FEMALE; HUMANS; ISCHEMIA; LOGISTIC MODELS; MALE; MIDDLE AGED; RISK FACTORS;

EID: 84879779391     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0066907     Document Type: Article

References (32)

1. Peripheral arterial disease in people with diabetes. Diabetes Care 26: 3333-3341.
2. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH, (1998) Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation 97: 425-428.
3. Singh D, Whooley MA, Ix JH, Ali S, Shlipak MG, (2007) Association of cystatin C and estimated GFR with inflammatory biomarkers: the Heart and Soul Study. Nephrol Dial Transplant 22: 1087-1092.
4. Laterza OF, Price CP, Scott MG, (2002) Cystatin C: an improved estimator of glomerular filtration rate? Clin Chem 48: 699-707.
5. Dharnidharka VR, Kwon C, Stevens G, (2002) Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis 40: 221-226.
6. Filler G, Bokenkamp A, Hofmann W, Le Bricon T, Martinez-Bru C, et al. (2005) Cystatin C as a marker of GFR-history, indications, and future research. Clin Biochem 38: 1-8.
7. Bokenkamp A, Herget-Rosenthal S, Bokenkamp R, (2006) Cystatin C, kidney function and cardiovascular disease. Pediatr Nephrol 21: 1223-1230.
8. Shlipak MG, Katz R, Sarnak MJ, Fried LF, Newman AB, et al. (2006) Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease. Ann Intern Med 145: 237-246.
9. Xie L, Terrand J, Xu B, Tsaprailis G, Boyer J, et al. (2010) Cystatin C increases in cardiac injury: a role in extracellular matrix protein modulation. Cardiovasc Res 87: 628-635.
10. Deo R, Shlipak MG, Ix JH, Ali S, Schiller NB, et al. (2009) Association of cystatin C with ischemia in patients with coronary heart disease. Clin Cardiol 32: E18-22.
11. O'Hare AM, Newman AB, Katz R, Fried LF, Stehman-Breen CO, et al. (2005) Cystatin C and incident peripheral arterial disease events in the elderly: results from the Cardiovascular Health Study. Arch Intern Med 165: 2666-2670.
12. Urbonaviciene G, Shi GP, Urbonavicius S, Henneberg EW, Lindholt JS, (2011) Higher cystatin C level predicts long-term mortality in patients with peripheral arterial disease. Atherosclerosis 216: 440-445.
13. Standards of medical care in diabetes-2012. Diabetes Care 35Suppl 1: S11-63.
14. Cheung BM, Ong KL, Wong LY, (2009) Elevated serum alkaline phosphatase and peripheral arterial disease in the United States National Health and Nutrition Examination Survey 1999-2004. Int J Cardiol 135: 156-161.
15. Baetta R, Corsini A, (2010) Role of polymorphonuclear neutrophils in atherosclerosis: current state and future perspectives. Atherosclerosis 210: 1-13.
16. Dijk JM, Wangge G, Graaf Y, Bots ML, Grobbee DE, et al. (2006) Hemoglobin and atherosclerosis in patients with manifest arterial disease. The SMART-study. Atherosclerosis 188: 444-449.
17. Ishizaka N, Ishizaka Y, Nagai R, Toda E, Hashimoto H, et al. (2007) Association between serum albumin, carotid atherosclerosis, and metabolic syndrome in Japanese individuals. Atherosclerosis 193: 373-379.
18. Wattanakit K, Folsom AR, Selvin E, Coresh J, Hirsch AT, et al. (2007) Kidney function and risk of peripheral arterial disease: results from the Atherosclerosis Risk in Communities (ARIC) Study. J Am Soc Nephrol 18: 629-636.
19. O'Hare AM, Glidden DV, Fox CS, Hsu CY, (2004) High prevalence of peripheral arterial disease in persons with renal insufficiency: results from the National Health and Nutrition Examination Survey 1999-2000. Circulation 109: 320-323.
20. Selvin E, Erlinger TP, (2004) Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999-2000. Circulation 110: 738-743.
21. Sheen YJ, Lin JL, Lee IT, Hsu YN, Li TC, et al. (2012) Low estimated glomerular filtration rate is a major determinant of low ankle-brachial index and toe-brachial index in type 2 diabetes. Angiology 63: 55-61.
22. Selvin E, Kottgen A, Coresh J, (2009) Kidney function estimated from serum creatinine and cystatin C and peripheral arterial disease in NHANES 1999-2002. Eur Heart J 30: 1918-1925.
23. Chen JH, Chen SC, Liu WC, Su HM, Chen CY, et al. (2009) Determinants of peripheral arterial stiffness in patients with chronic kidney disease in southern Taiwan. Kaohsiung J Med Sci 25: 366-373.
24. Chen J, Mohler ER, 3rd, Xie D, Shlipak MG, Townsend RR, et al (2012) Risk factors for peripheral arterial disease among patients with chronic kidney disease. Am J Cardiol 110: 136-141.
25. Shlipak MG, Praught ML, Sarnak MJ, (2006) Update on cystatin C: new insights into the importance of mild kidney dysfunction. Curr Opin Nephrol Hypertens 15: 270-275.
26. Koenig W, Twardella D, Brenner H, Rothenbacher D, (2005) Plasma concentrations of cystatin C in patients with coronary heart disease and risk for secondary cardiovascular events: more than simply a marker of glomerular filtration rate. Clin Chem 51: 321-327.
27. Ix JH, Shlipak MG, Chertow GM, Whooley MA, (2007) Association of cystatin C with mortality, cardiovascular events, and incident heart failure among persons with coronary heart disease: data from the Heart and Soul Study. Circulation 115: 173-179.
28. Knight EL, Verhave JC, Spiegelman D, Hillege HL, de Zeeuw D, et al. (2004) Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney Int 65: 1416-1421.
29. Lee SH, Park SA, Ko SH, Yim HW, Ahn YB, et al. (2010) Insulin resistance and inflammation may have an additional role in the link between cystatin C and cardiovascular disease in type 2 diabetes mellitus patients. Metabolism 59: 241-246.
30. Arpegard J, Ostergren J, de Faire U, Hansson LO, Svensson P, (2008) Cystatin C-a marker of peripheral atherosclerotic disease? Atherosclerosis 199: 397-401.
31. Shi GP, Sukhova GK, Grubb A, Ducharme A, Rhode LH, et al. (1999) Cystatin C deficiency in human atherosclerosis and aortic aneurysms. J Clin Invest 104: 1191-1197.
32. Eriksson P, Deguchi H, Samnegard A, Lundman P, Boquist S, et al. (2004) Human evidence that the cystatin C gene is implicated in focal progression of coronary artery disease. Arterioscler Thromb Vasc Biol 24: 551-557.